Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"National Institute of Health","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"Chrysalis BioTherapeutics Receives Funding from the National Institutes of Health for COVID-19 Therapeutic Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$10.4 million","upfrontCash":"Undisclosed","newsHeadline":"Chrysalis BioTherapeutics Receives $10.4 Million From BARDA to Continue Development of TP508 as a Nuclear Countermeasure","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed"},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chrysalis Receives FDA Approval to Initiate Clinical Trials with Chrysalin\u2122 (TP508)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Chrysalis BioTherapeutics

    Menu

    Chrysalis BioTherapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Chrysalis BioTherapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Chrysalis Receives FDA Approval to Initiate Clinical Trials with Chrysalin™ (TP508)

              Details:

              Chrysalin (rusalatide acetate) is a natural regenerative peptide that accelerates tissue repair and revascularization while modulating the inflammatory response, which is investigated for Acute Respiratory Distress Syndrome.

              Lead Product(s): Rusalatide Acetate

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Chrysalin

              Highest Development Status: IND Enabling Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Chrysalis BioTherapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Chrysalis BioTherapeutics Receives $10.4 Million From BARDA to Continue Development of TP508 as a Nuclear Countermeasure

              Details:

              Chrysalis will conduct safety studies and additional options required to achieve Emergency Use Authorization and Animal Rule approval for TP508 as a medicinal treatment for acute and delayed effects of ionizing radiation exposure.

              Lead Product(s): Rusalatide Acetate

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: TP508

              Highest Development Status: Undisclosed Product Type: Peptide

              Partner/Sponsor/Collaborator: BARDA

              Deal Size: $10.4 million Upfront Cash: Undisclosed

              Deal Type: Funding December 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Chrysalis BioTherapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development

              Details:

              Funding from the NIAID COVID-19 contract is being used to complete in vivo testing of TP508 efficacy, drug product manufacture, and regulatory steps to initiate clinical trials in COVID-19 patients.

              Lead Product(s): Rusalatide Acetate

              Therapeutic Area: Infections and Infectious Diseases Product Name: TP508

              Highest Development Status: Preclinical Product Type: Peptide

              Partner/Sponsor/Collaborator: National Institutes of Health

              Deal Size: $1.5 million Upfront Cash: Undisclosed

              Deal Type: Funding August 11, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Chrysalis BioTherapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Chrysalis BioTherapeutics Receives Funding from the National Institutes of Health for COVID-19 Therapeutic Development

              Details:

              This award will allow Chrysalis BioTherapeutics to evaluate TP508 as a potential solution to prevent thrombosis and systemic vascular damage caused by SARS-CoV-2 infection.

              Lead Product(s): Rusalatide Acetate

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: National Institute of Health

              Deal Size: $0.9 million Upfront Cash: Undisclosed

              Deal Type: Funding June 10, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY